New rheumatoid arthritis drug 'can succeed where others fail'
A new therapy for rheumatoid arthritis has shown potential to effectively treat patients who have failed to respond to other types of therapy.The new drug, baricitinib, is currently still in the clinical testing phase, but if approved it could represent a promising new therapeutic option for people with refractory rheumatoid arthritis, who currently have few options available to them.A new treatment approach Baricitinib was tested in a phase III clinical trial, led by Stanford University in the US and the Medical University of Vienna in Austria, to determine the drug's effectiveness in patients who had not benefited fr...
Source: Arthritis Research UK - April 5, 2016 Category: Rheumatology Source Type: news
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
A biosimilar version of the anti–tumor necrosis factor–alpha agent Remicade has been approved by the Food and Drug Administration, making it the first biosimilar drug approved by the agency for inflammatory diseases and just the second biosimilar it has approved.
The agency said in its April 5 <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 5, 2016 Category: Dermatology Source Type: news
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
A biosimilar version of the anti–tumor necrosis factor–alpha agent Remicade has been approved by the Food and Drug Administration, making it the first biosimilar drug approved by the agency for... (Source: Family Practice News)
Source: Family Practice News - April 5, 2016 Category: Primary Care Source Type: news
FDA Approves Rheumatoid Arthritis Knockoff
U.S. regulators cleared for sale a knockoff version of Johnson & Johnson’s Remicade anti-inflammatory drug, the second entry in a fledgling U.S. market for lower-cost copies of pricey biotechnology drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 5, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade
April 5, 2016 -- The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.
Inflectra is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 5, 2016 Category: Drugs & Pharmacology Source Type: news
FDA approves biosimilar to J&J's Remicade for multiple diseases
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson's drug Remicade, to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves Infliximab Biosimilar, Inflectra
(MedPage Today) -- Can be used for arthritis, psoriasis, and inflammatory bowel disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 5, 2016 Category: American Health Source Type: news
FDA approves Inflectra, a biosimilar to Remicade
The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 5, 2016 Category: American Health Source Type: news
Treatment Retention Better With Combo for Axial Disease (CME/CE)
(MedPage Today) -- Effects most notable with infliximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 5, 2016 Category: Primary Care Source Type: news
New study highlights long-term tolerability of anti-TNF therapies
This study provides reassuring evidence that anti-TNF therapies are effective in some patients over long periods of time; however, it also highlights the importance of selecting the right drug for each patient, as a large number of people with arthritis have to switch between therapies during a course of treatment."We are funding research which aims to help doctors predict which patients will respond best to which therapies, helping to speed up the time it takes to get the right treatment to the right patient." (Source: Arthritis Research UK)
Source: Arthritis Research UK - April 3, 2016 Category: Rheumatology Source Type: news
EMA Committee Backs Infliximab Biosimilar Product FlixabiEMA Committee Backs Infliximab Biosimilar Product Flixabi
Studies show 'comparable quality, safety and efficacy' to the reference product Remicade (infliximab), the committee noted. International Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 1, 2016 Category: Dermatology Tags: Rheumatology News Alert Source Type: news
Samsung Nears European Approval for Near-Replica Version of Arthritis Drug
Samsung Group’s drug-development arm said it is on track to win European regulatory approval for a near-replica version of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 1, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
Infliximab not cost effective for ulcerative colitis in Poland
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2016 Category: Drugs & Pharmacology Source Type: news
Benefits of anti-TNF treatment for psoriatic arthritis highlighted by study
This study was significant as it utilised data from patients in a real-world setting, rather than controlled test conditions. This provides doctors with a clearer view of how drugs work in routine clinical practice.A total of 420 biologic-naive patients with psoriatic arthritis, who were beginning treatment with the anti-TNF therapies adalimumab, etanercept or infliximab, were enrolled in the trial, with their progress followed over four years.Attention was paid to drug survival rates - the number of people remaining on treatment after a given period - as well as how many of the patients continued to rely on glucocorticoid...
Source: Arthritis Research UK - March 28, 2016 Category: Rheumatology Source Type: news
Head-to-Head Comparison of Infliximab, Adalimumab in Crohn'sHead-to-Head Comparison of Infliximab, Adalimumab in Crohn's
In a rare comparison of infliximab and adalimumab in patients with Crohn's disease, long-term outcomes were assessed in a 'real-life situation.' Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 22, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
